Published in final edited form as:

Bioessays. 2017 June ; 39(6): . doi:10.1002/bies.201600264.

C/D-box snoRNAs form methylating and non-methylating ribonucleoprotein complexes: Old dogs show new tricks

Marina Falaleeva¹, Justin R. Welden¹, Marilyn J. Duncan², and Stefan Stamm^{1,*}

¹University Kentucky, Institute for Biochemistry, Lexington, KY, USA

²University Kentucky, Department of Neuroscience, Lexington, KY, USA

Abstract

C/D box snoRNAs (SNORDs) are an abundantly expressed class of short, non-coding RNAs that have been long known to perform 2'-O-methylation of rRNAs. However, approximately half of human SNORDs have no predictable rRNA targets, and numerous SNORDs have been associated with diseases that show no defects in rRNAs, among them Prader-Willi syndrome, Duplication 15q syndrome and cancer. This apparent discrepancy has been addressed by recent studies showing that SNORDs can act to regulate pre-mRNA alternative splicing, mRNA abundance, activate enzymes, and be processed into shorter ncRNAs resembling miRNAs and piRNAs. Furthermore, recent biochemical studies have shown that a given SNORD can form both methylating and non-methylating ribonucleoprotein complexes, providing an indication of the likely physical basis for such diverse new functions. Thus, SNORDs are more structurally and functionally diverse than previously thought, and their role in gene expression is under-appreciated. The action of SNORDs in non-methylating complexes can be substituted with oligonucleotides, allowing devising therapies for diseases like Prader-Willi syndrome.

Keywords

alternative splicing; obesity; Prader-Willi syndrome; RNA methylation; RNA processing; RNA therapy; SNORD; snoRNA

The classic picture of snoRNAs

Small nucleolar RNAs are a highly expressed class of non-coding RNAs

Small nucleolar RNAs (**snoRNAs**) are an abundantly expressed class of non-coding RNAs (**ncRNA**) that accumulate in the nucleolus. They are about 60–300 nucleotides (**nt**) long and based on conserved sequence elements, snoRNAs are classified either as C/D box or H/ACA box. C/D box snoRNAs (**SNORDs**) contain C (RUGAUGA, R=purine) and D (CUGA) boxes, which are usually present in duplicates (C' and D' boxes) and up to two antisense

*Corresponding author: Stefan Stamm, stefan@stamms-lab.net.

Supplementary material online

Conflict of interest:

The authors declare no conflict of interest.

boxes hybridizing to the RNA target [1]. SNORDs are flanked by two termini that form a stem in the final SNORD ribonucleoprotein complex (**SNORNP**) (Figure 1A).

snoRNAs are highly expressed. For example, a typical mammalian cell contains an estimated 200,000 copies of SNORD3, and 20,000 copies of SNORD13/14 [2, 3], which compares to estimated 200,000 mRNA molecules in a cell [4]. snoRNAs are one of the longest and best studied ncRNAs, as their high expression allowed their sequencing using RNase-mapping in 1979 [5], shortly after Sanger sequencing became available [6].

Human SNORDs are located in introns and form ribonucleoprotein complexes through a multistep assembly process

Almost all of the currently known 267 human SNORDs are located in introns, with the exception of SNORD3@ (@ indicating all four human SNORD3 genes, see Box 1 for SNORD nomenclature), SNORD8, SNORD13, and SNORD118 (U8) that are controlled by their own promoters [7, 8]. The intronic localization connects SNORD biogenesis with the pre-mRNA processing of their hosting genes. After the splicing reaction, the introns are released as lariats, which are opened up by the debranching enzyme and are subsequently degraded through exonuclease where XRN1/2 acts on the 5' end and the RNA exosome at the 3' end [9, 10]. The close connection between pre-mRNA splicing and SNORD biogenesis is reflected by a distance requirement for SNORDs that are located around 33–40 nt upstream of the branch point, which was shown using biochemical studies on a few SNORDs [11,12]. SNORDs escape degradation by associating with proteins in a snoRNP precursor, where the stem-termini forming a dsRNA stem that protects from exonucleases (Figure 1B). Proteomic studies deciphered the snoRNP assembly pathway for human U3 snoRNA [13]. Central for the assembly is the R2TP complex (named after the yeast proteins ATPases Rvb1 and Rvb2 (named after E.Coli DNA repair enzyme *ruvB*), Pih1 (Protein interacting with Hsp90) and Tah1 (TPR-containing protein associated with Hsp90) [14]. The R2TP complex acts like a chaperone allowing the formation of complexes between proteins and snoRNA.

The R2TP complex components RUVBL1 and RUVBL2 associate with the SNORD core proteins *NHP2L1* (15.5k, *SNU13*) pre-bound to NUFIP and ZNHIT3, and NOP58 in an ATP-dependent manner, which releases PIH1D1 and RPAP3. This protein complex associates with the SNORD and fibrillarin, removing ZNHIT3. In a further maturation step, a second molecule of fibrillarin, as well as NOP56 enters the complex, removing the adaptors ZNHIT6 and NUFIP. Unloading of RuvBL1/2, leads to further rearrangement and generated the final snoRNP complex (Figure 1C). The components of this system are conserved from human to yeast, where it was shown that the R2TP components PIH1D1 and RPAP3 shuttle between cytosol and nucleus using the Crm1 and Kap121 export/import systems [15], which is regulated by the nutritional status of the cells via the mTOR pathway [15] (Figure 1D).

The described assembly pathway has been determined for SNORD3@, which are expressed under their own promoters, but given the similarity between snoRNP complexes, it is likely that intronic SNORDs follow a similar pathway. The knock-down of R2TP components in

yeast changes expression of several snoRNAs, suggesting that the general features of this pathway are conserved [16].

Intronic SNORDs use additional factors for maturation, for example, IBP160 (intron binding protein 160kd) that interacts with U2snRNP measures the distance between intron branch-point, likely allowing for a folding of the SNORD [12]. Another factor is the spliceosome component Prp43p that is associated with SNORDs, possibly helping to recycle SNORDs during rRNA processing [17] and whose loss leads to extended SNORD ends upon deletion [18].

snoRNP structureThe SNORD-ribonucleoprotein complex positions the methylase fibrillarin towards the target RNA

The final snoRNP consists of two molecules *NHP2L1* (15.5k, *SNU13*) bound to the RNA kink-turn formed by the C/D box interactions [19], one molecule of NOP56 and NOP58 bridging these structures and two molecules of fibrillarin [13], reviewed in [20] (Figure 1E). Detailed insight into SNORD complexes came from cryo-EM and NMR based structural studies from archaeal SNORDs [21, 22], demonstrating that *NHP2L1* (15.5k, *SNU13*) binds to the two RNA kinks formed by the interaction between the C and D and C' and D' boxes, forming a bipartite structure. These two domains are connected by NOP56 and NOP58, which is one molecule NOP5 in archaea. NOP5 stabilizes the binding of the methylase fibrillarin in this complex through direct interaction. The assembled SNORNPs form dimers, likely in a parallel orientation where the stems of the two monomers interact [22].

The SNORD RNA has two functions in this arrangement: first, it provides the scaffold for the RNP complex, by forming two RNA kink structures which locate 15.5/*NHP2L1* and by forming a double stranded terminal stem that protects the RNA from further exonucleic cleavage. Secondly, two elements of the SNORD, known as antisense boxes are not covered with proteins and are thus free to interact with target RNAs. The antisense boxes recognize sequences in target RNAs resulting in the fifth nucleotide upstream of the D or D' box being 2'-O-methylated by the methylase fibrillarin [1], which is properly positioned in the complex. The antisense boxes in eukaryotes vary in length (10–21 nt), but only a maximum of 10 nt can be used for modifications, due to the structure of the snoRNP [23]. With a few exceptions, such as the targeted U6 snRNA [24], SNORDs modify ribosomal RNAs at around 100 sites. Most of these modifications are constitutive and play a role in rRNA folding and translational fidelity [25]. However, some rRNA sites are only partially methylated and some SNORDs exhibit sequence complementarity to rRNAs without a resulting modification, which suggests additional functions for SNORDs [26,27]. A few SNORDs including SNORD3@ and U8 and U13 direct pre-rRNA cleavage [28]. In SNORD3@, the interaction with rRNA is mediated by SNORD3-specific sequences upstream of the C box [29].

Diseases caused by snoRNA loss indicate new functions

orphan snoRNAs Half of the known SNORDs are orphan, as they have no known target

The structure and targeting properties of SNORNPs allowed the identification of their likely targets through sequence comparisons using the known 2'-O-methylation sites of rRNA (Figure 1E). However, a target could be identified for only half of the known SNORDs. The remaining SNORDs were thus considered “orphan” [8, 30], suggesting that they might have other functions than 2'-O-methylation. The association of changes in SNORD expression with numerous diseases, where there were no obvious defects in ribosomal function, supports the concept that SNORDs mediate additional functions beyond rRNA methylation.

Loss of SNORD expression is critical for Prader-Willi syndrome (PWS)

Genetic defects in the 15q11.2-q13.1 regions provide some of the most striking examples of SNORDs functioning outside rRNA methylation. Due to imprinting, only the paternal allele of the 15q11.2-q13.1 region is expressed. Loss of the paternal allele, either through a deletion of the paternal allele or through uniparental disomy of the mother's allele leads to **Prader-Willi syndrome (PWS)**. PWS is one of the most frequent genetic causes of morbid obesity and intellectual disability in humans. It has a frequency of about 1:10,000–1:30,000 individuals. In early infancy, PWS is characterized by severe hypotonia, which improves in later infancy and is followed by excessive eating (hyperphagia), leading to morbid obesity when untreated. PWS subjects further show low growth hormone levels, short stature, hypogonadism, a characteristic behavior with temper tantrums, manipulative behavior and obsessive-compulsive symptoms [31].

The imprinted region lost in PWS contains four protein-coding genes and six orphan SNORDs located in the 3' UTR of the bicistronic SNURF-SNRPN gene. SNURF-SNRPN encodes the SNRPN protein, a member of the SmB protein family that forms spliceosomal snRNPs, and the nuclear SNURF (SNRPN upstream reading frame) protein of unknown function. The 3' UTR of this transcript hosts six orphan SNORDs, each flanked by two non-coding exons: SNORD107, -64, 108, -109a, -116 (29 copies falling into five distinct classes) and -115 (47 almost identical copies) (Figure 2A). The SNORDs are predominantly expressed in the brain, but can also be detected at lower levels in peripheral tissues [32]. The brain specificity increases towards 3' end of the SNRPN-SNURF transcript and SNORD115 can be detected only in neurons.

In addition to SNORDs, the Prader-Willi critical region generates five different snoRNA-related lncRNAs (sno-lncRNAs) consisting of the introns surrounded by one copy of SNORD116 on both 5' - and 3' -end. The function and generation of these sno-lncRNAs remains to be determined [33].

Microdeletions affecting SNORD116 identified in six individuals recapitulate several features of PWS in a PWS-like phenotype that can be clinically hard to detect. Comparing all microdeletions identifies a region containing SNORD116 and SNORD 109, suggesting that the loss of these SNORDs plays a central role in PWS disease etiology [34–38] (Figure 2A).

The gene dosage of SNORDs in this region can not only be modified by deletion, but also doubled through duplications of the 15q11.2-q13.1 regions. Paternal interstitial duplications of 15q11.2-q13.1 double the SNORD gene doses, leading to Duplication 15q syndrome (Dup15q). Paternal duplications show variable penetrance for autism, in which they may be asymptomatic or associated with phenotypes ranging from anxiety and sleep disturbance [39] to developmental delay [40]. Similarly, mice overexpressing SNORD115 show autistic features [41], illustrating that SNORD expression levels must be under tight control to prevent disease.

The complex phenotypes associated with alterations in SNORD expression in the 15q11.2-q13.1 region reveal the physiological importance of SNORDs and raise the question of their molecular function.

Changes of SNORD expression in many types of cancers

Changes in SNORD expression are also observed in several forms of cancer [42, 43]. For example, the chromosomal translocation breakpoint involved in some B-cell lymphomas is located in the non-protein coding gene SNHG5 (small nucleolar RNA host gene 5). SNHG5 harbors SNORD50A which methylates C(2848) of 28S rRNA [44] and is lost in numerous breast and prostate cancer cell lines and primary tumors [45–47]. The ncRNA gene GAS5 (growth arrest specific 5) regulates cell survival, possibly by sequestering glucocorticoid hormone receptors. GAS5 harbors 10 SNORDs, whose expression is highly associated with cancer prognosis [48–52] and SNORD78 from this cluster is a biomarker for lung cancer [53]. Similarly, the non-protein coding gene SNHG1 hosts SNORD-27, -25, -30, and -31 (Figure 2B). Loss of these SNORDs mark the progression of smoldering multiple myeloma, which cannot be explained through their predicted roles in rRNA methylation [54]. It is known that the localization and function of the R2TP complex that is necessary to form snoRNPs (Figure 1B, D) is regulated by the mTOR pathway [15] and likely altered in cancer [14, 55], which could affect snoRNP formation, but the molecular role of these SNORDs in cancer cannot be explained by their action on rRNA.

Some SNORDs mediate Lipotoxic stress and influence cholesterol trafficking

Another unexpected role of SNORDs was unveiled in a screen aimed at identifying factors that mediate lipotoxicity, the physiological response to lipid overload in non-adipose tissues, which is caused by obesity. When non-adipose cells are stimulated by high lipid concentration, they activate a stress response that involves activation of NADPH oxidase, leading to mitochondrial dysfunction and finally cell death. Surprisingly, deletion of the SNORDs -32a, 33, 34, and 35a prevents this lipotoxicity [56]. These four SNORDs, rather than the ribosomal protein L13A (RPL13A) in which they are located, mediate the blockade of lipotoxicity. Unexpectedly, this study also found that three of these SNORDs accumulate in the cytosol after treatment with fatty acids [56]. A later study using RNAseq analysis found that 94/119 expressed SNORDs can be detected in the cytosol after drug-induced lipotoxicity [57] and that the cytosolic accumulation of SNORDs is mediated by NADPH oxidases through an unknown mechanism [57]. As well as lipotoxicity, SNORDs participate in other processes, including glucose tolerance and cholesterol trafficking. Mice with a specific knock down of SNORD32A, 33, 34 and 35a that did not alter expression of the

protein encoded by the hosting genes RPL13A exhibited an increased systemic glucose tolerance and glucose-mediated insulin secretion [58]. Thus lack of these SNORDs promotes the clearance of circulating glucose possibly caused by decreased production of reactive oxygen species [58]. Using a similar screening system SNORD60 was found to act in intracellular cholesterol trafficking, which is independent of its suggested function in ribosomal RNA methylation [59]. SNORDs 32A, 33, 34, 35a and 60 are predicted to methylate ribosomal RNAs, but their role in lipotoxic stress and cholesterol trafficking, as well as their cytosolic function suggests additional functions. SNORD33 is also selectively increased in the serum of subjects with non-small cell lung carcinoma [60], but a possible link to lipotoxicity remains to be determined. It is well established that reactive oxidative species activate mTOR signaling [61], which regulates the snoRNP assembly factors of the R2TP complex (Figure 1D), providing a mechanistic link between reactive oxidative species and snoRNP formation.

The expression of some SNORDs oscillates in circadian rhythm

Deep sequencing (RNA-seq) of *Drosophila* brains collected at multiple timepoints during the day and night identified transcripts that exhibit 24-hour profiles [62]. As well as identifying robust daily oscillations in a large number of genes, similar to previous microarray studies, this study revealed that ~10% of the cycling genes are ncRNAs including snoRNAs. SNORDs in seven dUhgs (drosophila U22 host genes) exhibited oscillations that peaked during the light phase and appeared to be driven by light [62]. The majority of the Uhgs SNORDs are predicted to target rRNAs, although some of them are orphan. Because not all SNORDs exhibited a daily rhythm, those that do may have specialized functions related to daily rest-activity rhythms. If so, such a function might echo the proposed role of alterations in SNORDS in human diseases with the alterations in daily rest-activity rhythms. For example, patients with Prader-Willi syndrome or Duplication 15q syndrome exhibit alterations in daily sleep-wake cycles and in sleep architecture [31, 39, 63].

SNORDs as biomarkers for diseases and physiological changes

A subset of SNORDs change their expression in aging in *C. elegans*, [64]. In humans, alteration of cardiac SNORD expression is associated with the tetralogy of Fallot, a frequent congenital malformation of the heart [65]. SNORDs could further be markers of diseases, as SNORD3A is the RNA most strongly overexpressed in blood of Creutzfeldt-Jacob patients, as well as in mouse models of prion disease [66]. SNORD33, SNORD66 and SNORD76 or their fragments can also be detected in blood, where they may serve as biomarkers for non-small cell lung carcinoma [60]. The possible functionality of these SNORDs was tested in a proof of principle experiment, in which the addition of synthetic SNORD fragments to cell culture media led to an increase of several transcription factors and mRNAs involved in the innate immune response [67].

Similarly, SNORD126 is up-regulated in hepatocellular carcinoma and colorectal cancer and upregulates genes involved in the PI3-AKT pathway [68]. Osteoarthritis is the most common degenerative disease of the joints, characterized by joint cartilage breakdown that affects about 4% of the population. SNORD116 is up-regulated in posttraumatic osteoarthritis mouse models and horses with natural developed osteoarthritis, the latter show a four

hundred fold increase [69]. Smaller changes were observed for SNORD18, -49A, -58, -21, -27, -90 and 11.

Collectively, these reports suggest a role of SNORDs outside rRNA modification, as no defects in translation or general protein synthesis were associated with the diseases.

SNORDs form non-methylating ribonucleic protein complexes and are precursors for shorter RNAs

Understanding the role of SNORDs outside rRNA modification proved to be extremely difficult, predominantly because RNA targets cannot be bioinformatically predicted for most orphan SNORDs. Novel SNORD functions were indicated by genome wide RNA profiling of diseases that showed deregulation of numerous SNORDs, but gave little mechanistic insights [70–73] [65] [69]. A few SNORDs were analyzed in great detail using mostly transfection studies [74–76] and even transgenic mice [58, 77, 78], which gave insight in to physiological processes. Mechanistical insight has come from detailed biochemical analysis [79] and the development of new techniques identifying RNA:RNA interactions [80]. These diverse studies used human and mouse system and support the novel concept of SNORDs acting in non-methylating ribonucleic protein complexes, outlined here.

Since SnoRNA precursors contain complementary sequences, for example the future stems that inhibit degradation by exonucleases (Figure 1B). It is thus not surprising that some SNORDs are recognized by proteins binding to dsRNAs.

SNORD expressing units are precursors for miRNAs

miRNAs are generated from nuclear pri-miRNAs characterized by a stem-loop structure that is cut by the dsRNase drosha [81], leading to the export of a pre-miRNA into the cytosol, where it is further cleaved by dicer to 21 nt long miRNAs that are loaded onto argonaute proteins. The sequencing of RNAs associated with argonaute proteins that bind miRNAs revealed that several snoRNAs, both H/ACA and C/D box snoRNAs give rise to miRNAs [76, 82–85], previously reviewed in [70, 71]. Several studies showed a correlation between SNORD-derived miRNAs and diseases, for example cancer [55, 86]. Most of the studies rely solely on sequencing data, and thus the underlying biological mechanism and biological relevance of SNORD-derived miRNAs is unclear. However, several SNORD-derived miRNAs are associated with argonaute proteins, suggesting that they are functional in gene regulation [85].

SNORDs activate protein kinase R

The second dsRNA-binding protein identified to bind to SNORDs was protein kinase RNA-activated (**PKR**). PKR contains a double strand RNA binding domain whose activation of viral dsRNAs is well established. However, lipotoxic stress caused by palmitic acid also activates PKR and unexpectedly, SNORDs and H/ACA snoRNAs were found associated with activated PKR, suggesting that under metabolic stress conditions SNORDs mediate a stress response to PKR [87]. SNORDs associated with PKR included SNORD50A and 50B that are lost in some forms of cancer [45, 46]. SNORD50A/B were also found to directly

bind to K-Ras, which decreases G-protein binding and subsequently the activity of K-ras [88]. The loss of SNORD50A/B expression is thus predicted to increase Ras-ERK1/ERK2 signaling which could promote tumor formation. It is possible that in addition, PKR activation contributes to this process.

SNORDs can be precursors of piRNAs

SNORDs can also give rise to piRNAs, abundant 26–31 nt long non coding RNAs associated with PIWI proteins. The biogenesis of piRNAs is independent of DICER, and likely requires single stranded RNA [89]. One of these snoRNA-derived piRNAs, piR30840, works in nuclear-exosome mediated degradation of interleukin-4 pre-mRNA by recruitment of Ago4/Piwi4 to an intronic site [90].

SNORDs form non-methylating ribonucleoprotein complexes

SNORD115 was the first SNORD shown to regulate alternative splicing [75] and thus proteins associated with SNORD115 were the first to be analyzed, using direct pull down from total nuclear lysates [74] as well as pull downs from nuclear extracts fractionated through a density gradient [91]. Both approaches indicated that SNORD115 associates with proteins different from the canonical SNORD proteins: 15.5/NHP2L1, NOP56, NOP58 and fibrillarin (Figure 1E). SNORD115 associated with hnRNPs (A1, B1, A3, D0, hnRNPL2, ELAVL1), RNA helicases (DHX9, DDX), structural proteins (nucleolin, matrin3), and transcription factors (PURA). The number of these proteins and the broad distribution of SNORD115 complexes in glycerol gradients [91] suggested the presence of structurally diverse SNORD115-protein complexes.

Further insight into the composition of new SNORD complexes came from the analysis of HeLa nuclear extract fractionated under native conditions [79]. In this method nuclei are extracted using native salt conditions, which preserve higher order structure, and the extracts are subsequently separated on native glycerol gradients. Surprisingly, 29 SNORDs were found in nuclear fractions associated with the spliceosome, representing about 24% of the expressed SNORDs. Although most of these SNORDs have been previously shown to methylate rRNA, the nuclear fraction containing these SNORDs was devoid of fibrillarin, NOP58 and NOP56. A detailed analysis of SNORD27, predicted to perform the known 2'-O-methylation of A27 in 18S RNA [92], revealed that SNORD27 associated with diverse RNA binding proteins (FUBP3, FUBP1, KHSRP, hnRNPQ, L, ELAVL1,) and RNA helicases DDX5, as well as proteins implicated in splicing (PRPF3, PRPF4, SFPQ), which is reflected in the ability of SNORD27 to change splice site selection. The biochemical separation of SNORDs from fibrillarin-containing fractions was further confirmed using RNase protection for SNORD2, 60 and 78 [79].

SNORDs can be subdivided into two groups based on the number of paired nucleotides downstream of k-turn motif – one group has long ends (snoRNA_L) and the other one short ends (snoRNA_{SH}) [8]. The processing of snoRNA_L were more sensitive to NOP58 depletion, in contrast the processing of snoRNA_{SH} was affected by depletion of splicing factor RBFOX2. This additionally suggests that there is more than one processing pathway for SNORDs that could lead to generation of diverse RNPs.

Thus, the protein complexes formed by SNORD can be biochemically separated into complexes that contain fibrillarin (methylating SNORDs) and lacking fibrillarin (non-methylating SNORDs). Together, these data suggest that SNORDs form protein complexes that lack the methylase fibrillarin, which we refer to as **non-methylating SNORNPs** in addition to the well-known **methylating SNORNPs** containing 15.5/NHP2L1, NOP58, NOP56 and fibrillarin. Some SNORDs, like SNORD27, 2, 60 and 78 form both complexes and thus have dual functions [79]. SNORD3@ is atypical, because it is not an intronic SNORD, but shows that methylating SNORDs do not necessarily perform 2'-O-methylation. SNORD3@ cleaves pre-rRNA using an extra 5' sequence, containing A and B boxes that aid in rRNA cleavage site recognition. SNORD3@ also forms a classic methylating SNORNP that is used for nuclear localization, but not targeting [29].

Some SNORDs form shorter RNAs, processed snoRNAs (psnoRNAs)

Within the methylating SNORD-ribonucleoprotein particle, the RNA is protected from degradation by the associated proteins and a terminal stem. However, such a protection might not be the case in heterogenous and more loosely formed non-methylating SNORDs. Deep sequencing experiment showed the presence of SNORD fragments with a medium length longer than 27 nt, which distinguishes them from miRNAs having a length distribution of 21–22 nt [93, 94]. Using a cloning technique allowing the identification of SNORD-fragments detected by RNase protection analysis, the presence of SNORD fragments, termed psnoRNA for processed snoRNA was further confirmed for mouse SNORD115 and SNORD116 [73, 74]. The analysis of the human transcriptome using RNAseq showed the expression of psnoRNAs for the human 115, 116, 113, 114 families and SNORDs- 50, 19, 32B, 123, 111, 72, 93, 23 and 85 [72, 73], listed in Supplemental Figure 1.

Non-methylation snoRNPs could explain the presence of psnoRNAs, as not the whole SNORD RNA is protected in a well-folded non-methylating complex from the actions of RNases, but only shorter fragments are protected by RNA binding proteins. Inspection of the SNORDs known to generate psnoRNAs shows that with the exception of SNORD 115 none of these SNORDs has all four C, C' D and D' boxes in full consensus (Supplemental Figure 1), which could impair proper snoRNP folding.

What are the functions of non-methylating SNORDs?

The formation of non-methylating SNORDs can explain mechanistically the influence of SNORDs on gene expression, which could contribute to diseases caused by SNORD loss. As described above, due to the double-stranded nature of SNORD precursors, SNORDs can activate protein kinase R and SNORD fragments can become part of argonaute proteins, acting as miRNAs.

In addition, the function of SNORDs in non-methylating RNA:protein complexes is emerging. Glycerol gradient analysis shows a wide size distribution of non-methylating snoRNA-protein complexes [79,91], indicating their heterogeneity. The absence of the defined structures indicates that each part of the SNORD, not just the antisense boxes, is free to interact with other RNA molecules, which has been confirmed by detailed studies of SNORD:pre-mRNA interaction (Figure 2C–F).

SNORDs bind to pre-mRNAs, regulating splice site selection

SNORD115 (previously called HBII-52) is an orphan SNORD expressed in the Prader-Willi critical region (Figure 2A). It shares an 18 nt sequence complementarity with the alternative exon Vb of the serotonin receptor 2C and promotes the inclusion of this exon [75] due to direct SNORD:mRNA interaction (Figure 2C). SHAPE assays showed that the serotonin receptor 2C pre-mRNA in this region forms a stable double stranded structure that sequesters the regulated splice site, causing exon skipping [95] (Figure 3A). A chemical screen identified pyrvinium pamoate as a substance that binds to this double-stranded region, changes the structure, which de-represses the regulated splice site [95]. Since SNORD115 binds to the dsRNA structure, it likely acts through a similar structural change. The dsRNA of the serotonin receptor 2C pre-mRNA is stable enough to be A->I edited by ADAR2, which leads to exon activation by similarly disrupting the dsRNA area, which activates the regulated splice site [95,96]. SNORD115 has no influence of RNA editing, but changes the ratio between inclusion and skipping of a non-edited exon Vb into the serotonin receptor pre-mRNA through direct SNORD-pre-mRNA interaction.

Proof of principle experiments showed that SNORD115 can perform 2'-O-methylation of short artificial RNAs sent to the nucleolus by using reporter constructs driven by an RNA polymerase I promoter. SNORD115 can also influence editing of an RNA fragment corresponding to serotonin receptor 2C pre-mRNA when expressed under a RNA polymerase I promoter [97]. However, physiologically, the serotonin receptor 2C is controlled by a RNA polymerase II promoter and thus the endogenous transcripts are not associated with the nucleolus. SNORD115 knock out mice show a change in serotonin receptor 2C splicing, indicating that physiologically, SNORD115 changes splicing in the nucleoplasm [78].

SNORD27 has been known to methylate rRNA and the finding that it changes splice site selection similar to SNORD115 was thus surprising [79]. Bioinformatic prediction validated by mutational analysis showed that SNORD27 binds to the 5' splice sites of the E2F7 transcripts and most likely blocks U1 snRNP access, leading to exon skipping (Figure 2D). A similar effect was found for several exons that are only expressed in SNORD27's absence, suggesting that repression of exons is a general function of SNORD27. Importantly, SNORD27 also regulates 2'-O-methylation of rRNA [44], indicating that the SNORD has a dual function in both rRNA modification, acting in a methylating snoRNP and in alternative splice site selection, acting in a non-methylating RNP [79].

A similar dual function has been reported for SNORD88C, which is predicted to guide 28S rRNA methylation [7], but also regulates the alternative splicing of the *FGFR3* pre-mRNA [98], (binding sites indicated in Figure 2F).

SNORDs regulate gene expression by direct binding to RNA

A major impediment in understanding the interaction between non-methylating SNORDs and their target RNAs are the difficulties in determining the SNORD: target RNA interactions, as these interactions can occur across the whole SNORD molecule, not just the antisense boxes. Furthermore, RNA:RNA interactions are more promiscuous than

DNA:DNA interactions, allowing for example G:U base pairing and tolerating gaps. It is therefore not a surprise that the validation of bioinformatically predicted SNORD:pre-mRNA interaction is poor. This problem has persisted now for over 20 years [99], preventing the understanding of orphan SNORD function. Recently, **LiG**ation of interacting **R**NA and high-throughput sequencing (**LiGR**) was developed to detect RNA:RNA interaction [80]. In LiGR, RNAs are cross-linked with the psoralen derivative AMT (4'-**A**minomethyl-trioxsalen hydrochloride), a molecule selective for dsRNA, single stranded ends are trimmed with RNase R and the ligated RNAs sequenced. Using this method, an interaction between the orphan SNORD83B and three pre-mRNAs (NOP14, SRSF3 and RPS5) was detected. Knock-down of SNORD83B caused an increase of mRNA of these target genes, but not their pre-mRNA, suggesting that SNORD83B could regulate mRNA stability, (Figure 2E) [80]. Since the interaction between SNORD27 and E2F7 can be demonstrated by RNA pull down without crosslink [79] and was not detected using LiGR [80], it is likely that more SNORD-mRNA interaction exist.

A possible role of SNORDs in mRNA stability is also suggested by the overexpression of one copy of mouse SNORD116 in cells not expressing endogenous SNORD116, which changes the expression of about 200 mRNAs, but has no detectable influence on alternative splicing [100]. Thus, regulating mRNA stability, possibly similar to miRNAs [101] by competing with RNA stabilizing proteins, could be a more general function of non-methylating SNORDs.

The comparison of these SNORDs acting in splice site selection and mRNA expression shows an emerging common mechanism: the SNORDs associate with various RNA binding proteins, likely forming diverse non-methylating snoRNPs. The sequence complementarity between target and SNORD RNA includes sequences outside the antisense boxes, which should be taken into account in any prediction programs (Figure 2F).

Substitution of non-methylating SNORDs to combat human disease

The concept that SNORDs act in non-methylating protein complexes suggested therapeutic approaches for diseases caused by SNORD loss. Whereas a methylating SNORD complex has to be assembled during the splicing reaction from a large intron through several assembly steps (Figure 1B,C), it might be possible to substitute a non-methylating SNORD using an oligonucleotide that recapitulates the SNORD-mRNA interaction. The use of RNase-resistant modified oligonucleotides makes them independent from the binding of protecting proteins. This concept was first tested to influence alternative splicing of the serotonin receptor 2C, recapitulating the effect of SNORD115, the first SNORD shown to regulate splice site selection [102, 103].

The serotonin receptor 2C regulates food intake

The serotonin receptor 2C (**5HT2C**) regulates food uptake through its action on pro-opiomelanocortin (**POMC**) neurons in the hypothalamus. Activation of the 5HT2C receptor leads to an increase of phospholipase C, which activates c-fos leading to POMC synthesis in these neurons. Alpha-melanocyte stimulating hormone (alpha-MSH), which is generated by processing of the POMC precursor, activates neurons in the paraventricular nucleus (PVN)

via melanocortin 4 receptors [104,105]. Activation of PVN neurons induces satiety, i.e. cessation of eating (Figure 3E). Knock-out mice lacking the 5HT2C receptor thus exhibit hyperphagia and are obese [106], whereas activation of the 5HT2C receptor using an agonist such as the FDA approved drug, lorcaserin, inhibits food intake [107]. Since patients with Prader-Willi syndrome do not express SNORD115, they show a dysregulation of 5HT2C alternative splicing, as observed in mouse models of this syndrome [78].

The activity of the serotonin receptor 2C is regulated by its RNA processing

The 5HT2C pre-mRNA undergoes both pre-mRNA editing and splicing of its exon Vb, which generates at least 25 proteins that respond differently to serotonin binding [108, 109] (Figure 3C, D). Skipping of exon Vb generates **RNA1** encoding a **truncated receptor 5HT2C_tr** that is expressed as a protein [103]. The 5HT2C_tr is localized intracellularly and through heterodimerization sequesters the full-length receptor inside the cell [103,110], decreasing the receptor's activity. Exon Vb inclusion generates **RNA2**. RNA2 formation is promoted by SNORD115 [75], resulting in a **non-edited full-length receptor 5HT2C_FL_INI**, with the amino acids INI in the second intracellular loop. Editing through ADAR2 at five sites also promotes exon Vb inclusion, leading to 32 RNA2 isoforms. The editing changes three amino acids, leading to 23 **full-length, edited receptors, 5HT2C_FL_ed**. The non-edited 5HT2C_FL_INI is constitutively active and shows the strongest response to serotonin, whereas the edited isoforms show a weaker response to serotonin binding and their constitutive activity decreases with increased editing, with 5HT2C_FL_VGV having no constitutive activity [109, 111, 112]. Mouse models indicate that loss of the full length non-edited 5HT2C isoform causes hyperphagia [113], most likely because of the weak serotonin response of the edited receptors.

Central to this system is a stable secondary structure containing the alternative exon Vb that dictates the processing of the RNA [95, 96]. The default processing is skipping of Vb: exon Vb can be activated by disrupting this structure, either by the editing of guanosine to inosines, leading to full-length edited receptors, or by binding of SNORD115, which likely opens the dsRNA structure, leading to the non-edited full-length receptor (Figure 3A).

The truncated RNA1-encoded protein is localized in the intracellular membrane systems, likely the endoplasmic reticulum and Golgi and sequesters the full-length RNA2-encoded receptor [110]. Without RNA1, the full-length receptor is localized at the plasma membrane and throughout the cell [114]. Due to the sequestration, RNA1-encoded receptors reduce the presence of the full-length RNA2 receptor at the surface (Figure 3E). Thus, the RNA1/RNA2 isoform-ratio, which is controlled by SNORD115, regulates 5HT2C receptor activity by determining the surface concentration of the active receptor [110]. Because the SNORD115-5HT2C target interaction has been worked out (Figure 2C), efforts to find a substitution for SNORD115 concentrated on this system.

SNORD115 can be substituted with an oligonucleotide

Using an oligo-walk [115], an oligonucleotide, oligo#5 that strongly promotes exon Vb inclusion in cell culture [103], similar to SNORD115 was identified. Oligo#5 was then tested in vivo, by injecting it into the 3rd ventricle of wild-type C57/Bl6 mice. This treatment

with oligo#5 increased 5HT2C_FL_INI and decrease RNA1 in the hypothalamic arcuate nucleus, as expected, and importantly, robustly reduced food intake. Thus, SNORD115 can be functionally substituted using an oligonucleotide, which further shows that a methylase is not necessary for SNORD115 action. The data also indicate that the ratio between the two 5HT2C proteins: a full-length receptor containing exon Vb and a truncated receptor lacking it, is involved in the regulation of food intake. Since it is known that the full-length receptor heterodimerizes with other transmembrane receptors [116, 117], it is possible that this ratio, controlled by the non-methylating SNORD115 contributes to the formation of the complex Prader-Willi syndrome by affecting different receptor systems.

Conclusion and outlook: snoRNAs can have multiple roles by forming different RNPs – a general role for ncRNAs?

The reviewed evidence shows that SNORDs have broader functions and more diverse properties than previously assumed. SNORDs not only form the well-studied methylating complexes, but in addition associate with hnRNPs and dsRNA binding proteins to form non-methylating complexes. The compositional analysis of several non-methylating SNORD-protein complexes showed a high degree of diversity, indicating multiple functions.

Similar to other processes in RNA biology, such pre-mRNA splicing, a balance between RNA elements adhering to consensus sequences, distance requirements and trans-acting protein factors likely dictates whether a SNORD forms a methylating or non-methylating ribonucleoprotein protein complex. A stronger divergence from the perfect consensus sequences likely favors non-methylating snoRNPs, which is reflected by the presence of psnoRNAs. For some SNORDs, the same SNORD expressing unit can form both methylating and non-methylating complexes, and this balance could be caused by modification of factors needed to form methylating snoRNA complexes.

Once a SNORD or its fragment becomes metabolically stable in a non-methylating SNORD complex it can acquire new functions by binding to other nucleic acids. As in the methylating snoRNP, the function of the RNA is twofold: it acts as a scaffold for the proteins and it binds to other nucleic acids via base-pairing. Studies of SNORD27 showed that its pre-mRNA targets are not evolutionary conserved, suggesting that SNORDs are acquiring new functions during evolution. Non-methylating SNORDs could also explain why some SNORDs accumulate in the cytosol under stress [56, 57]. For example, HuR/ELVAL1 was found bound to all non-methylating SNORD complexes analyzed so far. HuR/ELVAL1 accumulates in the cytosol under oxidative stress condition [118] and thus could help transport associated non-methylating SNORDs out of the nucleus.

Due to the high expression of SNORDs –there are roughly as many SNORD3 transcripts as mRNA transcripts in a cell- SNORDs likely represent an important but underappreciated class of mRNA regulators.

Acknowledgments

Supported by the NIH (R21HD080035, R21NS098186 and the Foundation for Prader-Willi Research).

Abbreviations

ncRNA	non-coding RNA
PKR	protein kinase RNA
psnoRNA	processed snoRNA
PWS	Prader-Willi syndrome
SNORD	C/D box snoRNA
snoRNA	small nucleolar RNA
SNORNP	SNORD ribonucleoprotein complex

References

1. Filipowicz W, Pelczar P, Pogacic V, Dragon F. Structure and biogenesis of small nucleolar RNAs acting as guides for ribosomal RNA modification. *Acta Biochim Pol.* 1999; 46:377–89. [PubMed: 10547039]
2. Tyc K, Steitz JA. U3, U8 and U13 comprise a new class of mammalian snRNPs localized in the cell nucleolus. *EMBO J.* 1989; 8:3113–9. [PubMed: 2531075]
3. Maxwell ES, Fournier MJ. The small nucleolar RNAs. *Annu Rev Biochem.* 1995; 64:897–934. [PubMed: 7574504]
4. Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. *Nat Rev Genet.* 2013; 14:618–30. [PubMed: 23897237]
5. Reddy R, Henning D, Busch H. Nucleotide sequence of nucleolar U3B RNA. *J Biol Chem.* 1979; 254:11097–105. [PubMed: 500626]
6. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA.* 1977; 74:5463–7. [PubMed: 271968]
7. Lestrade L, Weber MJ. snoRNA-LBME-db, a comprehensive database of human H/ACA and C/D box snoRNAs. *Nucleic Acids Res.* 2006; 34:D158–62. [PubMed: 16381836]
8. Deschamps-Francoeur G, Garneau D, Dupuis-Sandoval F, Roy A, et al. Identification of discrete classes of small nucleolar RNA featuring different ends and RNA binding protein dependency. *Nucleic Acids Res.* 2014; 42:10073–85. [PubMed: 25074380]
9. Costello JL, Stead JA, Feigenbutz M, Jones RM, et al. The C-terminal region of the exosome-associated protein Rrp47 is specifically required for box C/D small nucleolar RNA 3'-maturation. *J Biol Chem.* 2011; 286:4535–43. [PubMed: 21135092]
10. Miki TS, Grosshans H. The multifunctional RNase XRN2. *Biochem Soc Trans.* 2013; 41:825–30. [PubMed: 23863139]
11. Hirose T, Steitz JA. Position within the host intron is critical for efficient processing of box C/D snoRNAs in mammalian cells. *Proc Natl Acad Sci USA.* 2001; 98:12914–9. [PubMed: 11606788]
12. Hirose T, Ideue T, Nagai M, Hagiwara M, et al. A spliceosomal intron binding protein, IBP160, links position-dependent assembly of intron-encoded box C/D snoRNP to pre-mRNA splicing. *Mol Cell.* 2006; 23:673–84. [PubMed: 16949364]
13. Bizarro J, Charron C, Boulon S, Westman B, et al. Proteomic and 3D structure analyses highlight the C/D box snoRNP assembly mechanism and its control. *J Cell Biol.* 2014; 207:463–80. [PubMed: 25404746]
14. Kakiyama Y, Saeki M. The R2TP chaperone complex: its involvement in snoRNP assembly and tumorigenesis. *Biomol Concepts.* 2014; 5:513–20. [PubMed: 25429602]
15. Kakiyama Y, Makhnevych T, Zhao L, Tang W, et al. Nutritional status modulates box C/D snoRNP biogenesis by regulated subcellular relocalization of the R2TP complex. *Genome Biol.* 2014; 15:404. [PubMed: 25060708]

16. Zhao R, Kakihara Y, Gribun A, Huen J, et al. Molecular chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that regulates snoRNA accumulation. *J Cell Biol.* 2008; 180:563–78. [PubMed: 18268103]
17. Leeds NB, Small EC, Hiley SL, Hughes TR, et al. The splicing factor Prp43p, a DEAH box ATPase, functions in ribosome biogenesis. *Mol Cell Biol.* 2006; 26:513–22. [PubMed: 16382143]
18. Banerjee D, McDaniel PM, Rymond BC. Limited portability of G-patch domains in regulators of the Prp43 RNA helicase required for pre-mRNA splicing and ribosomal RNA maturation in *Saccharomyces cerevisiae*. *Genetics.* 2015; 200:135–47. [PubMed: 25808954]
19. Schroeder KT, McPhee SA, Ouellet J, Lilley DM. A structural database for k-turn motifs in RNA. *RNA.* 2010; 16:1463–8. [PubMed: 20562215]
20. Massenet S, Bertrand E, Verheggen C. Assembly and trafficking of box C/D and H/ACA snoRNPs. *RNA Biol.* 2016; doi: 10.1080/15476286.2016.1243646
21. Lapinaite A, Simon B, Skjaerven L, Rakwalska-Bange M, et al. The structure of the box C/D enzyme reveals regulation of RNA methylation. *Nature.* 2013; 502:519–23. [PubMed: 24121435]
22. Yip WS, Shigematsu H, Taylor DW, Baserga SJ. Box C/D sRNA stem ends act as stabilizing anchors for box C/D di-sRNPs. *Nucleic Acids Res.* 2016; 44:8976–89. [PubMed: 27342279]
23. Yang Z, Lin J, Ye K. Box C/D guide RNAs recognize a maximum of 10 nt of substrates. *Proc Natl Acad Sci USA.* 2016; 113:10878–83. [PubMed: 27625427]
24. Tycowski KT, You ZH, Graham PJ, Steitz JA. Modification of U6 spliceosomal RNA is guided by other small RNAs. *Mol Cell.* 1998; 2:629–38. [PubMed: 9844635]
25. Decatur WA, Fournier MJ. rRNA modifications and ribosome function. *Trends Biochem Sci.* 2002; 27:344–51. [PubMed: 12114023]
26. Gumienny R, Jedlinski DJ, Schmidt A, Gypas F, et al. High-throughput identification of C/D box snoRNA targets with CLIP and RiboMeth-seq. *Nucleic Acids Res.* 2016; doi: 10.1093/nar/gkw1321
27. Krogh N, Jansson MD, Hafner SJ, Tehler D, et al. Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity. *Nucleic Acids Res.* 2016; 44:7884–95. [PubMed: 27257078]
28. Granneman S, Vogelzangs J, Luhrmann R, van Venrooij WJ, et al. Role of pre-rRNA base pairing and 80S complex formation in subnucleolar localization of the U3 snoRNP. *Mol Cell Biol.* 2004; 24:8600–10. [PubMed: 15367679]
29. Borovjagin AV, Gerbi SA. Xenopus U3 snoRNA GAC-Box A' and Box A sequences play distinct functional roles in rRNA processing. *Mol Cell Biol.* 2001; 21:6210–21. [PubMed: 11509664]
30. Smith CM, Steitz JA. Sno storm in the nucleolus: new roles for myriad small RNPs. *Cell.* 1997; 89:669–72. [PubMed: 9182752]
31. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome. *GeneReviews.* 2016 Internet.
32. Cavaille J, Buiting K, Kieffmann M, Lalande M, et al. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. *Proc Natl Acad Sci USA.* 2000; 97:14311–6. [PubMed: 11106375]
33. Yin QF, Yang L, Zhang Y, Xiang JF, et al. Long noncoding RNAs with snoRNA ends. *Mol Cell.* 2012; 48:219–30. [PubMed: 22959273]
34. Sahoo T, del Gaudio D, German JR, Shinawi M, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. *Nat Genet.* 2008; 40:719–21. [PubMed: 18500341]
35. Duker AL, Ballif BC, Bawle EV, Person RE, et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. *Eur J Hum Genet.* 2010; 18:1196–201. [PubMed: 20588305]
36. Bieth E, Eddiry S, Gaston V, Lorenzini F, et al. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi Syndrome. *Eur J Hum Genet.* 2015; 23:252–5. [PubMed: 24916642]
37. de Smith AJ, Purmann C, Walters RG, Ellis RJ, et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. *Hum Mol Genet.* 2009; 18:3257–65. [PubMed: 19498035]

38. Fontana P, Grasso M, Acquaviva F, Gennaro E, et al. SNORD116 deletions cause Prader-Willi syndrome with a mild phenotype and macrocephaly. *Clin Genet.* 2017; doi: 10.1111/cge.13005
39. Urraca N, Cleary J, Brewer V, Pivnick EK, et al. The interstitial duplication 15q11.2-q13 syndrome includes autism, mild facial anomalies and a characteristic EEG signature. *Autism Res.* 2013; 6:268–79. [PubMed: 23495136]
40. Finucane, BM., Lusk, L., Arkilo, D., Chamberlain, S., et al. 15q Duplication Syndrome and Related Disorders. In: Pagon, RA. Adam, MP. Ardinger, HH. Wallace, SE., et al., editors. *GeneReviews(R)*. Seattle (WA): 1993.
41. Nakatani J, Tamada K, Hatanaka F, Ise S, et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. *Cell.* 2009; 137:1235–46. [PubMed: 19563756]
42. Mannoor K, Liao J, Jiang F. Small nucleolar RNAs in cancer. *Biochim Biophys Acta.* 2012; 1826:121–8. [PubMed: 22498252]
43. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? *Nat Rev Cancer.* 2012; 12:84–8. [PubMed: 22257949]
44. Kiss-Laszlo Z, Henry Y, Bachellerie JP, Caizergues-Ferrer M, et al. Site-specific ribose methylation of preribosomal RNA: a novel function for small nucleolar RNAs. *Cell.* 1996; 85:1077–88. [PubMed: 8674114]
45. Dong XY, Guo P, Boyd J, Sun X, et al. Implication of snoRNA U50 in human breast cancer. *J Genet Genomics.* 2009; 36:447–54. [PubMed: 19683667]
46. Dong XY, Rodriguez C, Guo P, Sun X, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. *Hum Mol Genet.* 2008; 17:1031–42. [PubMed: 18202102]
47. Siprashvili Z, Webster DE, Johnston D, Shenoy RM, et al. The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. *Nat Genet.* 2015; 48:53–8. [PubMed: 26595770]
48. Tanaka R, Satoh H, Moriyama M, Satoh K, et al. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. *Genes Cells.* 2000; 5:277–87. [PubMed: 10792466]
49. Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. *Mol Cell Biol.* 1998; 18:6897–909. [PubMed: 9819378]
50. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, et al. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. *Oncogene.* 2009; 28:195–208. [PubMed: 18836484]
51. Mourtada-Maarabouni M, Hedge VL, Kirkham L, Farzaneh F, et al. Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). *J Cell Sci.* 2008; 121:939–46. [PubMed: 18354083]
52. Krell J, Frampton AE, Mirnezami R, Harding V, et al. Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer. *PLoS One.* 2014; 9:e98561. [PubMed: 24926850]
53. Su J, Liao J, Gao L, Shen J, et al. Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis. *Oncotarget.* 2016; 7:5131–42. [PubMed: 26246471]
54. Lopez-Corral L, Mateos MV, Corchete LA, Sarasquete ME, et al. Genomic analysis of high-risk smoldering multiple myeloma. *Haematologica.* 2012; 97:1439–43. [PubMed: 22331267]
55. Mannoor K, Liao J, Jiang F. Small nucleolar RNAs in cancer. *Biochim Biophys Acta.* 2012; 1826:121–8. [PubMed: 22498252]
56. Michel CI, Holley CL, Scruggs BS, Sidhu R, et al. Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. *Cell Metabolism.* 2011; 14:33–44. [PubMed: 21723502]
57. Holley CL, Li MW, Scruggs BS, Matkovich SJ, et al. Cytosolic accumulation of small nucleolar RNAs (snoRNAs) is dynamically regulated by NADPH oxidase. *J Biol Chem.* 2015; 290:11741–8. [PubMed: 25792744]
58. Lee J, Harris AN, Holley CL, Mahadevan J, et al. Rpl13a small nucleolar RNAs regulate systemic glucose metabolism. *J Clin Invest.* 2016; 126:4616–25. [PubMed: 27820699]

59. Brandis KA, Gale S, Jinn S, Langmade SJ, et al. Box C/D snoRNA U60 Regulates Intracellular Cholesterol Trafficking. *J Biol Chem.* 2013; 288:35703–13. [PubMed: 24174535]
60. Liao J, Yu L, Mei Y, Guarnera M, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. *Mol Cancer.* 2010; 9:198. [PubMed: 20663213]
61. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. *EMBO J.* 2010; 29:4118–31. [PubMed: 21113129]
62. Hughes ME, Grant GR, Paquin C, Qian J, et al. Deep sequencing the circadian and diurnal transcriptome of *Drosophila* brain. *Genome Res.* 2012; 22:1266–81. [PubMed: 22472103]
63. Bruni O, Verrillo E, Novelli L, Ferri R. Prader-Willi syndrome: sorting out the relationships between obesity, hypersomnia, and sleep apnea. *Curr Opin Pulm Med.* 2010; 16:568–73. [PubMed: 20814307]
64. Kato M, Chen X, Inukai S, Zhao H, et al. Age-associated changes in expression of small, noncoding RNAs, including microRNAs, in *C. elegans*. *RNA.* 2011; 17:1804–20. [PubMed: 21810936]
65. O'Brien JE Jr, Kibiryeva N, Zhou XG, Marshall JA, et al. Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. *Circ Cardiovasc Genet.* 2012; 5:279–86. [PubMed: 22528145]
66. Cohen E, Avrahami D, Frid K, Canello T, et al. Snord 3A: a molecular marker and modulator of prion disease progression. *PLoS One.* 2013; 8:e54433. [PubMed: 23349890]
67. Stepanov GA, Filippova JA, Nushtaeva AA, Kuligina EV, et al. Artificial Analogues of Circulating Box C/D RNAs Induce Strong Innate Immune Response and MicroRNA Activation in Human Adenocarcinoma Cells. *Adv Exp Med Biol.* 2016; 924:121–5. [PubMed: 27753032]
68. Fang X, Yang D, Luo H, Wu S, et al. SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2. *J Mol Cell Biol.* 2016; doi: 10.1093/jmcb/mjw048
69. Steinbusch MM, Fang Y, Milner PI, Clegg PD, et al. Serum snoRNAs as biomarkers for joint ageing and post traumatic osteoarthritis. *Sci Rep.* 2017; 7:43558. [PubMed: 28252005]
70. Falaleeva M, Stamm S. Processing of snoRNAs as a new source of regulatory non-coding RNAs: snoRNA fragments form a new class of functional RNAs. *BioEssays.* 2013; 35:46–54. [PubMed: 23180440]
71. Mleczko AM, Bakowska-Zywicka K. When small RNAs become smaller: emerging functions of snoRNAs and their derivatives. *Acta Biochim Pol.* 2016; 63:601–7. [PubMed: 27785480]
72. Jorjani H, Kehr S, Jedlinski DJ, Gumieny R, et al. An updated human snoRNAome. *Nucleic Acids Res.* 2016; 44:5068–82. [PubMed: 27174936]
73. Shen M, Eyraas E, Wu J, Khanna A, et al. Direct cloning of double-stranded RNAs from RNase protection analysis reveals processing patterns of C/D box snoRNAs and provides evidence for widespread antisense transcript expression. *Nucleic Acids Res.* 2011; 39:9720–30. [PubMed: 21880592]
74. Kishore S, Khanna A, Zhang Z, Hui J, et al. The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. *Hum Mol Genet.* 2010; 19:1153–64. [PubMed: 20053671]
75. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. *Science.* 2006; 311:230–2. [PubMed: 16357227]
76. Ono M, Scott MS, Yamada K, Avolio F, et al. Identification of human miRNA precursors that resemble box C/D snoRNAs. *Nucleic Acids Res.* 2011; 39:3879–91. [PubMed: 21247878]
77. Skryabin BV, Gubar LV, Seeger B, Pfeiffer J, et al. Deletion of the MBII-85 snoRNA gene cluster in mice results in postnatal growth retardation. *PLoS Genet.* 2007; 3:e235. [PubMed: 18166085]
78. Garfield AS, Davies JR, Burke LK, Furby HV, et al. Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite. *Mol Brain.* 2016; 9:95. [PubMed: 27931246]
79. Falaleeva M, Pages A, Matuszek Z, Hidmi S, et al. Dual function of C/D box snoRNAs in rRNA modification and alternative pre-mRNA splicing. *Proc Natl Acad Sci USA.* 2016; 113:E1625–34. [PubMed: 26957605]

80. Sharma E, Sterne-Weiler T, O'Hanlon D, Blencowe BJ. Global Mapping of Human RNA-RNA Interactions. *Mol Cell*. 2016; 62:618–26. [PubMed: 27184080]
81. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol*. 2014; 15:509–24. [PubMed: 25027649]
82. Scott MS, Avolio F, Ono M, Lamond AI, et al. Human miRNA precursors with box H/ACA snoRNA features. *PLoS Comput Biol*. 2009; 5:e1000507. [PubMed: 19763159]
83. Scott MS, Ono M, Yamada K, Endo A, et al. Human box C/D snoRNA processing conservation across multiple cell types. *Nucleic Acids Res*. 2012; 40:3676–88. [PubMed: 22199253]
84. Brameier M, Herwig A, Reinhardt R, Walter L, et al. Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs. *Nucleic Acids Res*. 2011; 39:675–86. [PubMed: 20846955]
85. Ender C, Krek A, Friedlander MR, Beitzinger M, et al. A human snoRNA with microRNA-like functions. *Mol Cell*. 2008; 32:519–28. [PubMed: 19026782]
86. Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A, Pigman B, et al. C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. *Oncotarget*. 2015; 6:17430–44. [PubMed: 26041889]
87. Youssef OA, Safran SA, Nakamura T, Nix DA, et al. Potential role for snoRNAs in PKR activation during metabolic stress. *Proc Natl Acad Sci USA*. 2015; 112:5023–8. [PubMed: 25848059]
88. Siprashvili Z, Webster DE, Johnston D, Shenoy RM, et al. The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. *Nat Genet*. 2016; 48:53–8. [PubMed: 26595770]
89. Ku HY, Lin H. PIWI proteins and their interactors in piRNA biogenesis, germline development and gene expression. *Natl Sci Rev*. 2014; 1:205–18. [PubMed: 25512877]
90. Zhong F, Zhou N, Wu K, Guo Y, et al. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes. *Nucleic Acids Res*. 2015; 43:10474–91. [PubMed: 26405199]
91. Soeno Y, Taya Y, Stasyk T, Huber LA, et al. Identification of novel ribonucleo-protein complexes from the brain-specific snoRNA MBII-52. *RNA*. 2010; 16:1293–300. [PubMed: 20484469]
92. Tycowski KT, Shu MD, Steitz JA. A mammalian gene with introns instead of exons generating stable RNA products. *Nature*. 1996; 379:464–6. [PubMed: 8559254]
93. Taft RJ, Glazov EA, Lassmann T, Hayashizaki Y, et al. Small RNAs derived from snoRNAs. *RNA*. 2009; 15:1233–40. [PubMed: 19474147]
94. Kawaji H, Nakamura M, Takahashi Y, Sandelin A, et al. Hidden layers of human small RNAs. *BMC Genomics*. 2008; 9:157. [PubMed: 18402656]
95. Shen M, Bellaousov S, Hiller M, de La Grange P, et al. Pyrvinium pamoate changes alternative splicing of the serotonin receptor 2C by influencing its RNA structure. *Nucleic Acids Res*. 2013; 41:3819–32. [PubMed: 23393189]
96. Flomen R, Knight J, Sham P, Kerwin R, et al. Evidence that RNA editing modulates splice site selection in the 5-HT_{2C} receptor gene. *Nucleic Acids Res*. 2004; 32:2113–22. [PubMed: 15087490]
97. Vitali P, Basyuk E, Le Meur E, Bertrand E, et al. ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs. *J Cell Biol*. 2005; 169:745–53. [PubMed: 15939761]
98. Scott MS, Ono M, Yamada K, Endo A, et al. Human box C/D snoRNA processing conservation across multiple cell types. *Nucleic Acids Res*. 2012; 40:3676–88. [PubMed: 22199253]
99. Steitz JA, Tycowski KT. Small RNA chaperones for ribosome biogenesis. *Science*. 1995; 270:1626–7. [PubMed: 7502072]
100. Falaleeva M, Surface J, Shen M, de la Grange P, et al. SNORD116 and SNORD115 change expression of multiple genes and modify each other's activity. *Gene*. 2015; 572:266–73. [PubMed: 26220404]
101. Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. *Adv Exp Med Biol*. 2013; 768:97–126. [PubMed: 23224967]

102. Kishore S, Stamm S. Regulation of alternative splicing by snoRNAs. *Cold Spring Harb Symp Quant Biol.* 2006; 71:329–34. [PubMed: 17381313]
103. Zhang Z, Shen M, Gresch P, Ghamari-Langroudi M, et al. Oligonucleotide-induced alternative splicing of serotonin 2C receptor reduces food intake. *EMBO Mol Med.* 2016; 8:878–94. [PubMed: 27406820]
104. Cone RD. Anatomy and regulation of the central melanocortin system. *Nat Neurosci.* 2005; 8:571–8. [PubMed: 15856065]
105. Heisler LK, Cowley MA, Kishi T, Tecott LH, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. *Ann N Y Acad Sci.* 2003; 994:169–74. [PubMed: 12851313]
106. Tecott LH, Sun LM, Akana SF, Strack AM, et al. Eating disorder and epilepsy in mice lacking 5-HT_{2c} serotonin receptors. *Nature.* 1995; 374:542–6. [PubMed: 7700379]
107. Shukla AP, Kumar RB, Aronne LJ. Lorcaserin Hcl for the treatment of obesity. *Expert Opin Pharmacother.* 2015; 16:2531–8. [PubMed: 26472579]
108. Olaghere da Silva UB, Morabito MV, Canal CE, Airey DC, et al. Impact of RNA editing on functions of the serotonin 2C receptor in vivo. *Front Neurosci.* 2010; 4:26. [PubMed: 20582266]
109. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, et al. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. *J Biol Chem.* 1999; 274:9472–8. [PubMed: 10092629]
110. Martin CB, Ramond F, Farrington DT, Aguiar AS Jr, et al. RNA splicing and editing modulation of 5-HT_{2C} receptor function: relevance to anxiety and aggression in VGV mice. *Mol Psychiatry.* 2013; 18:656–65. [PubMed: 23247076]
111. Wang Q, O'Brien PJ, Chen C-X, Cho D-SC, et al. Altered G Protein-Coupling Functions of RNA Editing Isoform and Splicing Variant Serotonin 2C Receptors. *J Neurochem.* 2000; 74:1290–300. [PubMed: 10693963]
112. Werry TD, Loiacono R, Sexton PM, Christopoulos A. RNA editing of the serotonin 5HT_{2C} receptor and its effects on cell signalling, pharmacology and brain function. *Pharmacol Ther.* 2008; 119:7–23. [PubMed: 18554725]
113. Morabito MV, Abbas AI, Hood JL, Kesterson RA, et al. Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi Syndrome. *Neurobiol Dis.* 2010; 39:169–80. [PubMed: 20394819]
114. Marion S, Weiner DM, Caron MG. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. *J Biol Chem.* 2004; 279:2945–54. [PubMed: 14602721]
115. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. *RNA.* 2004; 10:1291–305. [PubMed: 15272122]
116. Schellekens H, van Oeffelen WE, Dinan TG, Cryan JF. Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. *J Biol Chem.* 2013; 288:181–91. [PubMed: 23161547]
117. Schellekens H, De Francesco PN, Kandil D, Theeuwes WF, et al. Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction. *ACS Chem Neurosci.* 2015; 6:1186–97. [PubMed: 25727097]
118. Kodiha M, Stochaj U. Nuclear transport: a switch for the oxidative stress-signaling circuit? *J Signal Transduct.* 2012; 2012:208650. [PubMed: 22028962]
119. Kishore S, Gruber AR, Jedlinski DJ, Syed AP, et al. Insights into snoRNA biogenesis and processing from PAR-CLIP of snoRNA core proteins and small RNA sequencing. *Genome Biol.* 2013; 14:R45. [PubMed: 23706177]

Box 1**Nomenclature of SNORDs**

SNORDs have a confusing nomenclature, reflecting more than 30 years of research on these RNAs. The HUGO name is SNORD for small nucleolar RNA C/D box, followed by a unique number. Identical SNORDs made from different hosting genes are depicted with an @, such as SNORD3@. SNORDs in gene clusters have their position indicated, such as SNORD115-1. Historically, small nuclear RNAs were termed U for Uracil-rich, and given a number, such as U1, U2, U3, etc. Some of these small nuclear RNAs were later to be recognized as SNORDs, such as U3. Newly discovered snoRNAs were given consecutive numbers, which did not discriminate between C/D and H/ACA box snoRNAs. Sometimes these numbers have more meaning, for example U27 (now SNORD27) is predicted to guide methylation of A27 of the 18S rRNA. The numbers in SNORD and U names are usually the same, but there are exceptions, for example U8 is now SNORD118. Sequencing projects identified new SNORDs that were given names related to libraries, for example HBII-52, now SNORD115, was named after human brain library II, clone 52 and similarly MBII-52 stands for mouse brain library. Nomenclature questions can be best addressed by referring to the snoRNA database (www-snoRNA.biotoul.fr) or the genecard database (<http://www.genecards.org>).

Figure 1.

Structure and formation of methylating snoRNP complexes. **A:** General structure of C/D box snoRNAs (SNORDs) Overall structure of a C/D box snoRNA. **C, D:** C and D boxes, with consensus sites indicated. Yellow circles indicate the stem termini, short regions that are complementary to each other. **M:** middle box, defined in some SNORDs acting in pre-mRNA processing, **AS:** antisense box. **B:** Excision of intronic SNORDs. The SNORD (thick line flanked by circles depicting the termini) is located in an intron ~33–40 nt upstream the branch point (bp). Boxes indicate the flanking exons. In the lariat the sequence between the

branchpoint and the SNORD is occupied by IBP160, which likely facilitates in folding the SNORD. The lariat structure is opened through the debranching enzyme and then degraded by exonucleases (red half circles). This RNA structure forms the SNORDRNP complex by interacting with proteins assembled by the R2TP complex. C: Formation of the snoRNP. Proteins associated with the mature snoRNP are shown in pink, the R2TP components RuvBL1/2 in gray and auxiliary factors in orange. The R2TP complex assembles with a preformed 15.5/NUFIP/ZNHIT3 complex, and NOP58 and ZHHIT6, which requires ATP bound to RuvBL1/2. This protein complex binds to the nascent snoRNA in a step that incorporates fibrillarin (Fib) and releases ZNHIT3. The snoRNP further matures due to the addition of the second fibrillarin molecule and NOP56, releasing ZHHIT6 and NUFIP. The RUVBL1/L2 complex catalyzes the final structural arrangements and is recycled as the R2TP complex after release of the mature snoRNA. Note that this pathway has been worked out for SNORD3@, which is not an intronic RNA, but one regulated by its own promoter and due to the sequence conservation, it is likely that intronic SNORDs follow the same maturation pathway. D: The activity and intracellular localization of the R2TP complex is regulated by the mTOR pathway sensing nutritional status and possibly other phosphatidylinositol 3' kinase-related kinases (PIKK), which was shown in yeast. E: Structure of a methylating SNORNP. The SNORD forms a protein complex made of 15.5 (also known as SNU13 and NHP2L1), NOP56/58 and the methylase fibrillarin (Fib) that 2'-O-methylates (H₃CO-) rRNA at a defined position (5 nt upstream of the D box). The coloring of the SNORD is similar to Figure 1A. Circles indicate the base interaction within the RNA kink. Only one antisense box is shown in rRNA targeting, but both antisense boxes can be used. The structure is adopted from an archaea snoRNP, based on NMR and cryo-EM studies [21, 22]. In the diagram, we used a shorter stem, which is 2–5 nt in humans [8, 119] and substituted the archaea single NOP5 protein with the human NOP56 and NOP58 proteins.

Figure 2. SNORDs involved in human disease and their function outside rRNA methylation. A: Schematic structure of Prader-Willi syndrome critical region (PWSCR). Genes are ovals, SNORDs are gray lines. Each SNORD is surrounded by two non-coding exons as shown in the insert above. IC: imprinting center, BP: breakpoint, cen: centromer, tel: telomer The microdeletions identified in four patients leading to a PWS-like phenotype [34–37] are indicated. B: Schematic structure of the SNHG1 (small nucleolar RNA host gene 1) harboring SNORD27, -25, -30, and -31 marking the progression of smoldering multiple

myeloma. SNHG1 is a non-protein coding gene, consisting of exon (boxes) that flank the SNORDs (gray lines). C: Binding of SNORD115 to the alternative exon Vb of the serotonin receptor 2C, identified by bioinformatic prediction [32] and validated by mutation analysis [75]. The D box is highlighted. D: Binding of SNORD27 to the alternative exon in the E2F7 pre-mRNA, experimentally validated through mutagenesis [79]. C and D boxes are shown, as well as the binding of the methylating snoRNP to 18S rRNA, leading to the modification of A27. Small letters indicate the intron. E: Interaction between SNORD83B three mRNA targets which regulates their expression levels as determined by LiGR [80]. F: Scheme of interactions between SNORDs and pre-mRNA targets. The schematic structure of a SNORD is shown and the site of interaction with various pre-mRNA and mRNAs indicated by lines. Note that the sites of interaction include the C and D boxes.

Figure 3.

Substituting SNORD115 with an oligonucleotide. A: Secondary structure of the serotonin receptor 2C pre-mRNA that encompasses exon Vb between the proximal (PS) and distal (DS) splice sites (yellow). Intron V is shown in small letters. In this structure, the distal splice site is blocked and the proximal site used. Binding of SNORD115 to the boxed site likely causes a structural change, similar to binding of pyriminium pamoate [95], which activates the distal site. Editing of up to four adenosines (red boxes) to guanosines similarly activates the distal splice site by weakening the RNA stem. Oligo#5 complementary to the green region strongly activates the distal site [103]. B: Gene structure of the 5HT2C. Exons are shown as boxes and the alternative splice patterns indicated by dashed lines. The region

in (A) is indicated by a yellow box and the location of oligo#5 is shown. The start codon in exon III is indicated by a round arrow. Skipping of exon Vb results in an early stop codon (open square arrow), whereas its inclusion results in a later stop codon (black square arrow). C: RNA isoforms generated by the processing events. Exon Vb skipping generates RNA1 and its inclusion generates RNA2. Due to editing combinations, RNA2 represents 32 RNA isoforms. SNORD115 and oligo#5 promote the inclusion of the non-edited exon Vb. D: Protein isoforms generated by the processing events. RNA2 encodes 24 isoforms, one non-edited isoform 5HT2C_FL_INI with the amino acids INI in the second intracellular loop and 23 isoforms (5HT2C_FL_ed) that are edited. Circles in the second intracellular loop of the serotonin receptor 2C indicated non-edited amino acids and stars depict the editing events. E: Effect of the isoform ratios in on signaling POMC-neurons. Left: 5HT2C_tr is present in intracellular membranes (ER/golgi) and sequesters the full-length receptor, stopping its signaling at the plasma membrane (PM). The lack to signaling does no inhibit food intake, such generating an orexic response. Right: A relative decrease of 5HT2C_tr caused by SNORD115 or oligo#5 leads to an increased occupation the full-length receptors at the plasma membrane surface and its signaling via the phospho lipase C (PLC) pathway. PLC activation induces c-fos, which activates POMC transcription. The resulting POMC peptide is processed into alpha Melanocyte-stimulating hormone (α MSH), which activates Melanocortin 4 receptors (MCR4) receptors in the paraventricular nucleus, which results in an anorexic behavior response.

Figure 4.

SNORDs generate methylating and non-methylating complexes. It is likely that there are differences in processing between individual SNORDs and this scheme summarizes general features. A: Generation of snoRNAs: Almost all human SNORDs are intronic and are released from their hosting genes through pre-mRNA splicing, debranching of the lariat and exonucleic trimming. The location of a SNORD flanked by terminal stems in a hosting intron is shown; the boxes depict exons. The released RNA forms different ribonucleic protein (RNP) complexes: Methylating snoRNPs and non-methylating snoRNPs. B: Methylating SNORDs are generated using the R2TP system (RUVBL1/2) [20], which is regulated by mTOR pathways. Methylating SNORDs perform 2'-O-methylation of rRNA in the nucleolus. In addition, SNORD3@, containing the methylase fibrillarin (fib) acts in rRNA cleavage. The structure of a methylating SNORNP, consisting of a terminal stem, two kinks formed by C and D boxes are shown. The SNORD binds to the target rRNA via its antisense boxes and performs 2'-O-methylation at a specific rRNA ribose, 5 nt downstream of the D box. C: Non-methylating SNORDs are generated through the association of

SNORDs with diverse proteins, either dsRNA binding proteins (blue, PKR: protein kinase R, drosha) or hnRNPs and other RNA binding proteins (grey circles, ovals). SNORDs activate PKR and can be processed by drosha similar to miRNAs, leading to their incorporation in to argonaute proteins (ago). SNORDs stabilized by hnRNPs bind directly to pre-mRNA via RNA-RNA interaction and change pre-mRNA alternative splicing [74] and mRNA expression [80], likely through changing the stability of the mRNA. Some of the SNORDs in non-methylating RNPs are further processed into psnoRNAs [70], possibly protected by hnRNPs from further degradation. The association of non-methylating SNORDs with shuttling proteins, such as HuR could explain their detection in the cytosol, which is promoted by NADPH superoxidase function [57].